Item 1.01. Entry Into a Material Definitive Agreement.

Effective October 26, 2009, Urigen Pharmaceuticals, Inc. (the "Company") entered into an Amendment to Senior Secured Convertible Promissory Notes with Platinum-Montaur Life Sciences, LLC ("Platinum"). Pursuant to the terms of the Amendment, the maturity dates of the following Notes issued by the Company to Platinum were extended through April 9, 2010: (A) Senior Secured Convertible Promissory Note No. 1 dated January 9, 2009 in the principal amount of $257,000; (B) Senior Secured Convertible Promissory Note No. 2 dated April 22, 2009 in the principal amount of $40,000; and (C) Senior Secured Convertible Promissory Note No. 3 dated August 13, 2009 in the principal amount of $202,500.

Item 7.01. Regulation FD Disclosure.

On October 29, 2009, the Company issued a press release concerning the foregoing. A copy of such press release is being furnished as Exhibit 99.1 to this current report on Form 8-K.

The information in this Item 7.01 of this current report on Form 8-K, together with the information in Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. Such information shall not be deemed incorporated by reference into any registration statement or other document filed with the SEC.

Item 9.01. Financial Statements and Exhibits

Exhibit Description Number 10.1 Amendment to Senior Secured Convertible Promissory Notes dated as of October 26, 2009. 99.1 Press Release dated October 29, 2009

---